The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients With Untreated Aggressive B-Cell Lymphoma

32 views
July 18, 2024
Comments 0
Login to view comments. Click here to Login